retatrutide trial results today The experimental GLP-1 drug 'reta' also improved blood sugar and heart health metrics. But side effects led more than 1 in 10 to drop out of trials early: https://bit.ly/4x6Aexb Retatrutide Achieves Up to 30.3%

The pharmacokinetics, safety, and tolerability of oral semaglutide were also studied in patients ( N = 56) with varying degrees of hepatic impairment (normal function, mild, moderate, and severe) over ten doses [37]

A 2025 JACC Case Reports case documented an interaction consistent with this model: tirzepatide producing a 27 bpm supine heart rate increase in a POTS patient approximately nine times the mean reported in non-POTS populations attributed by the authors to compromised autonomic regulation of cardiac output distribution (Hedge et al., 2025)

Use the calculator above to estimate volume in mL , units on a U-100 insulin syringe , total medication in the vial , estimated doses per vial , and estimated weeks of medication based on one injection per week

Dehydration is a top cause of fatigue

The kicker is that my endocrinologist recommended a GLP-1 to treat my hypoglycemia